{
  "attach_pages": "3",
  "attach_size": "762",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP202004291378986900_1.pdf?1588178481000.pdf",
  "company_code": "80385468",
  "eitime": "2020-04-29 16:41:21",
  "extend": {},
  "info_code": "AP202004291378986900",
  "language": "0",
  "notice_date": "2020-04-29 00:00:00",
  "notice_title": "2020Q1疫情影响下实现15%营收增长，研发新冠疫苗&EC获批添亮点",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "researcher": "唐爱金",
  "security": [
    {
      "market_uni": "0",
      "publish_relation": [
        {
          "originalCode": "1044",
          "publishName": "生物制品"
        }
      ],
      "short_name": "智飞生物",
      "short_name_ch": "智飞生物",
      "short_name_cht": "智飛生物",
      "short_name_en": "ZHIFEI-BIOL",
      "stock": "300122"
    }
  ],
  "short_name": "智飞生物",
  "source_sample_name": "广州广证恒生市场研究"
}